EXELIXIS, INC. (EXEL) Latest Company News

Oct 13, 2026, 00:34 UTC
Kuehn Law, PLLC announced an investigation into whether certain EXELIXIS, INC. officers and directors breached fiduciary duties to shareholders through potential self-dealing.
Source:
- prnewswire.com
Sep 24, 2026, 21:58 UTC
The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.
Source:
Sep 11, 2026, 11:30 UTC
The U.S. Food and Drug Administration extended by three months its review of Exelixis' experimental colorectal cancer drug combination, as disclosed by Exelixis in a filing on Friday.
Source:
Sep 4, 2026, 15:54 UTC
Handa Biotechnology announced that its new anticancer drug HND-039 (Omcazio capsules) received final approval from the US FDA, allowing it to enter the US market, with the originator's patent expiring in late August and a citizen petition dismissed.
Source:
- money.udn.com
Aug 31, 2026, 18:30 UTC
The U.S. Court of Appeals for the Federal Circuit affirmed a key portion of the 2024 District Court judgment in favor of Exelixis in its patent litigation against MSN Laboratories, upholding the decision that three patents covering Exelixis' product are valid and infringed.
Source:
- businesswire.com
Aug 5, 2026, 20:05 UTC
Exelixis, Inc. reported its financial results for the second quarter of 2026 and provided a corporate update on its commercial, clinical, and pipeline development milestones.
Source:
Jun 23, 2026, 19:26 UTC
Exelixis reported clinical trial data for its drug zanzalintinib in colorectal cancer, which missed statistical significance in overall survival for a key subgroup.
Source:
- zacks.com

EXEL

Kuehn Law, PLLC announced an investigation into whether certain EXELIXIS, INC. officers and directors breached fiduciary duties to shareholders through potential self-dealing.

The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.

The U.S. Food and Drug Administration extended by three months its review of Exelixis' experimental colorectal cancer drug combination, as disclosed by Exelixis in a filing on Friday.

Handa Biotechnology announced that its new anticancer drug HND-039 (Omcazio capsules) received final approval from the US FDA, allowing it to enter the US market, with the originator's patent expiring in late August and a citizen petition dismissed.

The U.S. Court of Appeals for the Federal Circuit affirmed a key portion of the 2024 District Court judgment in favor of Exelixis in its patent litigation against MSN Laboratories, upholding the decision that three patents covering Exelixis' product are valid and infringed.

Exelixis, Inc. reported its financial results for the second quarter of 2026 and provided a corporate update on its commercial, clinical, and pipeline development milestones.

Exelixis reported clinical trial data for its drug zanzalintinib in colorectal cancer, which missed statistical significance in overall survival for a key subgroup.